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Abstract
We evaluate the utility of the National Surveys of Attitudes and Sexual Lifestyles (Natsal)
undertaken in 2000 and 2010, before and after the introduction of the National Chlamydia
Screening Programme, as an evidence source for estimating the change in prevalence of
Chlamydia trachomatis (CT) in England, Scotland and Wales. Both the 2000 and 2010 surveys
tested urine samples for CT by Nucleic Acid Amplification Tests (NAATs). We examined the
sources of uncertainty in estimates of CT prevalence change, including sample size and adjust-
ments for test sensitivity and specificity, survey non-response and informative non-response.
In 2000, the unadjusted CT prevalence was 4.22% in women aged 18–24 years; in 2010, CT
prevalence was 3.92%, a non-significant absolute difference of 0.30 percentage points (95%
credible interval −2.8 to 2.0). In addition to uncertainty due to small sample size, estimates
were sensitive to specificity, survey non-response or informative non-response, such that
plausible changes in any one of these would be enough to either reverse or double any likely
change in prevalence. Alternative ways of monitoring changes in CT incidence and prevalence
over time are discussed.
Introduction
Chlamydia trachomatis (CT) is the most commonly diagnosed sexually transmitted infection
and a substantial cause of reproductive ill-health in women [1]. The National Chlamydia
Screening Programme (NCSP) was introduced in England in 2003 and was active nationwide
by 2008. The objectives of the NCSP have been twofold: to protect individual young women
who are infected from reproductive damage by identifying and treating them and their part-
ners, and to lower the population prevalence, and thereby lower the risk of CT transmission.
The NCSP has been operational with targets designed to meet these objectives for over 10
years, although doubts about its benefits continue to be raised [2–6]. In 2017, over 1.3 million
chlamydia tests were carried out among young people aged 15–24 years, of which 9.8% were
positive. Assuming one test per person, an estimated 28% of young females and 11% of young
males were tested for chlamydia [7].
The National Surveys of Sexual Attitudes and Lifestyles (Natsal) [8–10] are key sources of
policy-relevant data on reproductive and sexual health in Great Britain. The Natsal-2 and -3
surveys undertaken in 2000–01 and 2010–12, respectively, were stratified cross-sectional prob-
ability sample surveys of the general population resident in England, Scotland and Wales. The
surveys included inviting a random sub-sample of survey responders aged 16–44 years to pro-
vide urine samples which were tested for CT by Nucleic Acid Amplification Tests (NAATs).
Previous analyses of Natsal data have suggested that CT prevalence in 18–24 years old women
had barely changed between 2000, before the introduction of the NCSP (3.1%; 95% CI 1.8–5.2
in 18–24 years old), and 2010 after its introduction (3.2%; 95% CI 2.2–4.6) [8]. These figures
include adjustments for the different distributions of prevalence-related covariates in respon-
ders and non-responders. Subsequently, adjustments for assay sensitivity and specificity were
explored [11].
The objective of this paper is to evaluate the utility of Natsal surveys as a data source on CT
prevalence and CT prevalence change between 2000 and 2010, during which time screening
was introduced. More generally, we want to highlight the methodological issues that arise
when using surveys of this kind to estimate the population prevalence of sexually transmitted
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infections. The original rationale for this work was to support a
separate exercise of modelling age- and time-specific seropreva-
lence data from surveys such as the PHE Seroepidemiology Unit
[12] and Health Survey for England [13] to recover estimates of
age- and time-specific incidence. Both surveys would generate
predictions of age-specific incidence in 2000 and 2010, and the
intention had been to validate results against estimates of CT inci-
dence, which would be derived from Natsal CT prevalence using
estimates of the duration of CT infections from Price et al. [14].
Ultimately, it was hoped that the Natsal estimates could be used
to calibrate the estimates from seroprevalence models using multi-
parameter evidence synthesis [15].
Several issues require consideration before drawing conclu-
sions about CT prevalence from these surveys. First, the overall
net response rates, defined as the proportion of those invited
to participate in the original Natsal surveys, who were invited
to provide a urine sample, and who did so, were very low:
45.4% and 34.6% in 2000 and 2010, respectively [9]. The non-
participation bias corrections that have been published [8, 11,
16] consist of inverse propensity score (PS) reweighting [17],
which reweights the responding population so that its covariate
distribution matches that of the target population. The effect
of these adjustments was to lower CT prevalence estimates
[10], apparently because groups at higher risk of CT infection
(e.g. those reporting a higher number of partners, heterosexual
anal sex and STI diagnosis) were more prevalent among respon-
ders than non-responders. The premise underlying PS reweight-
ing is that, at any specific covariate pattern, the prevalence in
responders and non-responders is identical, so that the only
adjustment that is required is to reweight the covariate distribu-
tion in the responders so that it matches the overall (target)
population.
This premise is not supported by the ClaSS study [18, 19],
where CT prevalence among those who responded to the initial
invitation was considerably lower than in those who responded
to the subsequent invitations, although this is not adjusted for
covariates. An adjustment for non-response that addresses this
will increase the estimate of CT prevalence [11].
A further complication is the Natsal-2 and -3 surveys used dif-
ferent NAATs to measure CT prevalence. The Abbot Diagnostics
Ligase chain reaction (LCx) test [8] was used in Natsal-2, and the
Aptima AC2 followed by a further confirmatory assay in
Natsal-3. Woodhall (2015) [11], using data from a study compar-
ing the two assays [20], concluded that the sensitivity of LCx
relative to AC2 was 91.1% (i.e. using AC2 as a gold standard),
and its specificity was 99.1% (95% credible interval (CrI) 98.0–
99.7). However, it can be shown (see Appendix 1) that such a
low specificity is not compatible with a CT prevalence as low
as the 0.75% that was observed in 35–44 years old women, as
it implies, we should expect a 0.9% prevalence due to false posi-
tives alone.
In this paper, we consider a range of adjustments: for test
accuracy, for propensity to respond to the urine survey and for
non-response bias, to make some quantitative projections regard-
ing changes in CT prevalence between 2000 and 2010, based on
the Natsal surveys. Our intention is not so much to generate
definitive estimates; it is rather to generate a range of estimates
based on reasonable assumptions, in order to identify the key dri-
vers of uncertainty, in the hope of guiding future research efforts.
We include both statistical uncertainties originating in sampling
variation, and structural uncertainty which arises from uncertain
modelling assumptions.
Methods
We adopted a Bayesian approach, using Markov chain Monte
Carlo in WinBUGS 1.4.3 [21]. Throughout convergence was
achieved within 10 000 iterations. Posterior inference was based
on a total 200 000 samples from two chains after discarding the
first 20 000.
Our target parameters are the age-specific CT prevalence in
women in 2000 and 2010 in the general population resident in
England, Scotland and Wales, with age grouped into the ranges
16–17, 18–19, 20–24, 25–29, 30–34 and 35–44. From these we
derived estimates of CT prevalence change between 2000 and
2010. The process of mapping from the CT prevalence observed
in the Natsal surveys to unbiased estimates of CT prevalence in
the general population can be conceptualised in four steps:
(1) Adjustments for sensitivity and specificity of the assays.
(2) Adjustment for restriction of the urine survey to the sexually
experienced population.
(3) EITHER (a) Use of PSs to re-weight the numerators and
denominators in the urine sample population so that the cov-
ariate distribution matches the general population.
(4) OR (b) Further adjustments for non-response to allow for dif-
ferences in CT prevalence in responders and non-responders.
We now detail each step.
Crude unadjusted estimate
The observed data are the binomial numerator ra and denomin-
ator na at each age a. We begin with the crude, unadjusted, esti-
mate of prevalence ra  binomial (p(1)a , na), using a vague prior
log it(p(1)a )  N(−3, 102) centred on a prevalence of approxi-
mately 0.5% (95% CrI 1E-10–2.5E7). This ensures that prior
has negligible impact on the posterior results.
Adjustment for sensitivity and specificity in NAAT assays
Using a copy of the data, and the same prior (ra  binomial (p(2)a ,
na); log it(p(2)a )  N(−3, 102)), we estimate a second parameter
p(2)a . Then, an estimate of CT prevalence adjusted for sensitivity
and specificity, p(3)a , can be recovered via the relationship:
p(2)a = p(3)a ∗S+ (1− p(3)a )∗F. (1)
Note that the estimates p(2)a are updated by both the observed
data and the sensitivity and specificity corrections, and their pos-
teriors therefore differ from p(1)a . p
(2)
a thus represents the preva-
lence we would expect to observe if there was no correction for
sensitivity and specificity, while accounting for imperfect test
accuracy.
We have assumed that the joint specificity of AC2 and its con-
firmatory test is 99.9% (95% CrI 99.7–99.99). Regarding the spe-
cificity of LCx, a series of analyses in the 1990s [22–24] suggested
that the specificity of LCx was around 99.9%. These methods
employed what was referred to as an ‘expanded reference stand-
ard’. Subsequently, this method, under the name of ‘discrepancy
analysis’, was subjected to repeated criticism from statisticians
[25], to the extent that it is no longer used. Nevertheless, other
investigators using a methodology based on repeat testing con-
firmed that the specificity of LCx was likely to exceed 99.5%
[26]. Accordingly, we have assumed that the specificity of LCx
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was 99.8%, with a 95% CrI approximately 99.7–99.9%. Sensitivity
analyses were run assuming specificity of 99.5% with 95% CrI
99.1–99.9%.
For sensitivity of AC2, we carried out a random-effects
meta-analysis of five studies and obtained a mean estimate
94.95% with 95% CrI 93.39–96.52 (see Appendix 2 for details).
For LCx we have set LCx per cent sensitivity at 1.5 points
below AC2, i.e. at 93.45%, and have run a sensitivity analyses in
which sensitivity is 3.0% points below AC2 (91.95%), approxi-
mately the same as estimates based on Gaydos [20].
These assumptions about sensitivity and specificity of LCx dif-
fer somewhat from those that have been used in previous analyses
[11], which were based on Gaydos [20]. Appendix 1 presents an
analysis which suggests that the specificity assumed (99.1%) was
unrealistically low and incompatible with the observed Natsal-2
data.
We assumed throughout that prevalence would be allowed to
influence the test accuracy parameters.
Estimates for the general population
The Natsal-2 urine survey and the Natsal-3 urine survey were
designed to estimate CT prevalence in the sexually experienced
population aged 18–44 years. If the proportion who were sexually
experienced in age group a is κa we adjust the estimates p(3)a as
follows: p(4)a = kap(3)a .
Construction of balancing weights
The probability θi,a that a woman i aged a provided a valid urine
sample, given that she is a member of the general female popula-
tion aged a was estimated by a logistic regression:
log it(ui,a) = BTXi,a where Xi,a is a vector of covariates and B
their estimated coefficients. From this we derive weights for
each individual woman, wia = u−1ia in the survey. We have used
the same weights as in earlier studies [8, 11], slightly adjusted
because eligibility for the urine surveys was those participants
reporting that they were sexually experienced and our target par-
ameter is CT prevalence in the general population aged 16–44.
Among the key variables adjusted for were geographic region,
educational status, the total number of sexual partners, sexual
behaviour and previous STI diagnoses. Using the individual
weights wia we can form weights applicable to the aggregated
numerators and denominators:
Ra =
∑
i wiayia
ra
,Na =
∑
i wia
na
,
where yia is an indicator, 1 if iwas CT+ and otherwise 0. We can
derive an estimate of prevalence rebalanced to allow for the differ-
ent covariate mix in responders and non-responders:
p(5)a = p(4)a Ra/Na. Note that these rebalanced estimates incorpor-
ate the corrections for sensitivity and specificity and sexual behav-
iour. Note also that the weights are assumed to be estimated
without error.
Adjustment for non-response
In the ClaSS study, CT prevalence in those responding to the sub-
sequent postal invitation, phone call or home visit was higher
than those responding to the initial postal invitations, with an
odds ratio (OR) of 1.48 (95% CrI 1.03–2.11). We construct a
sixth estimate of CT prevalence, which adjusts the population esti-
mates p(4)a , as follows:
p(6)a = q.p(4)a + (1− q).p(NR)a ,where log it(p(NR)a )
= LOR+ log it(p(4)a ),
where LOR is the log OR for CT prevalence in non-responders
relative to responders, and q is the probability of responding.
Note that while the adjustments for non-response and PS
reweighting are both attempts to address biases arising from the
incomplete response to the survey and the likelihood that non-
responders have different CT prevalence, we view them as alter-
natives, and therefore do not apply both. This is taken up further
in discussion.
In the ClaSS study, the response rate to the initial postal invi-
tations in women aged 16–24 years was only 25.3%, going up to
30.4% after a second postal invitation, which is almost identical to
the net response rate to the urine sample in Natsal-3, and eventu-
ally to 36.4% at a third follow-up. In our base-case analysis, we
apply the OR from the ClaSS study (1.48) to the Natsal-2 and
Natsal-3 surveys, conservatively assuming that the same OR
applies to all non-responders in both surveys. As a sensitivity ana-
lysis, we consider a higher OR (1.90), which is well within the 95%
CrI of the ClaSS estimate (95% CrI 1.0–2.1). We also examine
scenarios in which the OR is greater by 10% in Natsal-3, on the
basis that response rate was lower and so the CT prevalence in
non-responders likely to be relatively higher. This gives adjust-
ments as follows: Natsal-2: 1.48, Natsal-3: 1.63; and Natsal-2:
1.90, Natsal-3: 2.09.
The purpose of this paper is to reveal the nature and the extent
of the uncertainties in estimates of prevalence change. We there-
fore document the span of the posterior credible intervals arising
from sampling uncertainty in the original data and in the other
inputs, and the impact of the sensitivity analyses on the posterior
mean change in prevalence. The WinBUGS code and datasets are
given in full in Appendix 3, so that readers can examine other
outputs and carry out further sensitivity analyses.
Results
Table 1 sets out age-specific CT prevalence estimates from
Natsal-2 and -3, respectively, starting with the crude estimates,
then sensitivity-specificity-adjusted estimates. The latter adjust-
ments are incorporated into both the PS reweighted estimates,
and the response-bias corrected estimates.
The crude estimates of change suggest an absolute fall of 0.30
percentage points (95% CrI −2.8 to 2.0) in CT prevalence in 18–
24 years old women from 4.22% to 3.92%. The span of the 95%
interval is 4.8 percentage points, not only far exceeding the central
estimate, but greater than the estimates of prevalence themselves.
In 25–44 years old, there was a fall of 0.38 percentage points (95%
CrI −1.1 to 0.4) from 1.54% to 1.16%, a credible span of 1.4 per-
centage points, again comparable with the incidence estimates
themselves.
The effect of the sensitivity adjustment described in equation 1
is to increase estimated prevalence by a multiplicative factor, so
the increase in prevalence is highest in younger women, who
have the highest observed prevalence. However, the effect of the
specificity adjustment reduces the estimates, as it interprets a pro-
portion of the observed positives as false positives. This latter
effect is more marked in the older groups, where observed
Epidemiology and Infection 3
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prevalence is low (Table 1). Goodness of fit statistics (not shown)
do not suggest a conflict between the prevalence data and the sen-
sitivity and specificity assumptions. Thus, as seen in Table 1, the
two adjustments tend to cancel out, so that following sensitivity
and specificity corrections, the CT prevalence appears to have
fallen by 0.27 percentage points in 18–24 years old with a slightly
larger uncertainty span of 5.2 percentage points due to uncer-
tainty in the adjustments, and by 0.31 percentage points in 25–
44 years old with an uncertainty span of 1.7 percentage points
(Table 1).
The net effect of the PS reweighting is to lower CT prevalence
in almost every cell (Table 1), because responders tended to be
disproportionately in groups with higher CT risk, as noted in earl-
ier work [8]. The size of the correction was especially marked in
20–24 years old in Natsal-2 and 30–34 years old in Natsal-3. The
net effect across all ages is similar in both surveys, with the pre-
dicted change in CT prevalence now being a rise of 0.04 percent-
age points in the younger group, and a fall of 0.23 percentage
points in the older. The uncertainty intervals are shrunk down-
wards (3.7 and 1.3 percentage points in the younger and older,
Table 1.
Crude prevalence p(1)a Sens/Spec corrected
a p(3)a PS re-weighting p
(5)
a
Non-response
correctedb p(6)a
Age group
CT
+ N Mean 95% CrIc Mean 95% CrI Mean 95% CrI Mean 95% CrI
(a) Posterior mean CT prevalence and change in prevalence in 2000 in women according to age, without adjustment (crude prevalence) and under different
adjustments for sensitivity and specificity, propensity score reweighting for covariate imbalance and correction for informative non-responsed.
Natsal-2: 2000
18–19 4 103 3.89 (1.1–8.3) 3.83 (0.7–
8.6)
3.45 (0.7–7.7) 4.66 (0.9–10.6)
20–24 12 276 4.35 (2.3–7.0) 4.42 (2.2–
7.4)
2.67 (1.3–4.4) 5.50 (2.6–9.4)
25–29 11 400 2.75 (1.4–4.6) 2.70 (1.2–
4.6)
2.05 (0.9–3.5) 3.41 (1.5–6.1)
30–34 9 472 1.91 (0.9–3.3) 1.78 (0.7–
3.3)
1.35 (0.5–2.5) 2.28 (0.8–4.4)
35–44 6 804 0.75 (0.3–1.4) 0.41 (0.0–
1.2)
0.33 (0.0–1.0) 0.52 (0.0–1.6)
Average 18–24 4.22 (2.4–6.5) 4.25 (2.3–6.7) 2.89 (1.5–4.6) 5.26 (2.8–8.6)
Average 25–44 1.54 (1.0–2.2) 1.32 (0.7–2.0) 1.02 (0.6–1.6) 1.69 (0.9–2.7)
(b) Posterior mean CT prevalence and change in prevalence in 2010 in women according to age, without adjustment (crude prevalence) and under different
adjustments for sensitivity and specificity, propensity score reweighting for covariate imbalance and correction for informative non-response.
Natsal-3: 2010
16–17 5 171 2.93 (1.0–5.9) 2.91 (0.8–6.1) 2.32 (0.7–4.9) 3.82 (1.1–8.2)
18–19 11 224 4.91 (2.5–8.1) 5.03 (2.5–8.4) 3.88 (1.9–6.5) 5.33 (2.5–9.2)
20–24 21 597 3.52 (2.2–5.1) 3.57 (2.2–5.3) 2.55 (1.5–3.8) 4.36 (2.5–6.8)
25–29 16 650 2.46 (1.4–3.8) 2.45 (1.3–3.8) 2.16 (1.2–3.4) 3.16 (1.6–5.3)
30–34 7 496 1.41 (0.6–2.6) 1.33 (0.4–2.6) 0.79 (0.2–1.5) 1.74 (0.5 –3.6)
35–44 2 527 0.38 (0.0–1.1) 0.14 (0.0–0.8) 0.10 (0.0–0.6) 0.18 (0.0–1.1)
Average 18–24 3.92 (2.7–5.3) 3.99 (2.7–5.5) 2.93 (2.0–4.1) 4.64 (2.9–6.9)
Average 25–44 1.16 (0.7–1.7) 1.01 (0.6–1.6) 0.79 (0.5–1.2) 1.32 (0.7–2.2)
Change 2000–
2010
Age 18–24 −0.30 (−2.8 to
2.0)
−0.27 (−3.0 to 2.2) 0.04 (−1.9 to
1.8)
−0.63 (−4.0 to
2.4)
Age 25–44 −0.38 (−1.1 to
0.4)
−0.31 (−1.2 to 0.5) −0.23 (−0.9 to
0.4)
−0.37 (−1.5 to
0.7)
aLCx specificity 99.8%; AC2 specificity 99.9%; AC2 sensitivity 94.95%; LCx sensitivity 1.5% less than AC2.
c95% Credible intervals.
bNon-response OR = 1.48 and remains the same for both 2000 and 2010.
dEach new adjustment is additional to sensitivity and specificity adjustments, e.g. propensity score re-weighting is applied on estimates corrected for imperfect sensitivity and specificity and
adjustment for informative non-response is applied on estimates corrected for imperfect sensitivity and specificity.
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respectively) in approximately the same proportion as the preva-
lence estimates themselves. Note that the PS-reweighting methods
used here [8] take no account of the uncertainty in the weights, so
that posterior uncertainty is under-estimated.
If instead of PS reweighting, we apply the same non-response
correction to both Natsal-2 and -3 (Table 1), based on the ClaSS
data, then we estimate a fall of 0.63 percentage points between the
two surveys for the 18–24 group, and a fall of 0.37 percentage
points in the 25–44 group. However, due to the uncertainty in
the ClaSS estimates, the uncertainty spans increase to 6.4 and
2.2 percentage points in the 18–24 and 25–44 years old groups,
respectively.
Results of additional sensitivity analyses are given in Table 2.
As with Table 1, three sets of results are given for each scenario:
adjustment for sensitivity and specificity; the same adjustment
with additional PS-reweighting; and the sensitivity and specificity
adjustment with an adjustment for differential non-response. The
first row (Scenario 0) is the base-case analysis from Table 1. In
Scenario 1, all parameters are held at the base-case values except
that the specificity of the LCx assay reduced from 99.8% to 99.5%.
This very small change leads to a predicted increase in the preva-
lence of 0.49 in the younger group and 0.24 percentage points in
the older, with similar results if either PS-reweighting or non-
response adjustment is adopted as well. By contrast, results are
robust against changes in NAAT sensitivity (Scenario 2 of
Table 2). By attributing more of the observed Natsal-2 prevalence
to false positives, the effect is to make it appear more likely that
prevalence has risen. Perhaps surprisingly, estimates of change
in prevalence are quite insensitive to an increase in the OR
from 1.48 to 1.90 (Scenario 3). However, if we allow the OR cor-
rection to be 10% greater in Natsal-3 than in Natsal-2, which
could be justified by the lower response rate in Natsal-3, this
again acts to make prevalence appear to have risen, or to have
fallen less (Scenarios 4 and 5).
Table 3 summarises the impact of modelling assumptions
examined in Table 2, by asking: ‘how much difference would it
make to the estimate of CT prevalence change if we choose one
modelling approach compared to another?’. The table shows
how each modelling contrast is constructed from Table 2 results.
Three modelling choices are examined. First (Row 1), adopting
PS-reweighting instead of adjustment for informative non-
response would change the estimate of prevalence change by
0.66% points in 18–24 years old, and 0.11 in 25–44 years old.
Second, the choice between the 99.8% and 99.5% LCx specificity
has an impact on CT prevalence change that is equal to, or larger
than, the base-case prevalence changes in both age groups, how-
ever non-participation is handled (Row 2). Finally (Row 3), differ-
ential non-response adjustments in the 2000 and 2010 surveys
have a major impact on predictions in the younger group, but
less for the older.
Discussion
This paper provides a re-analysis of the CT prevalence estimates
in Natsal-2 and -3, adding to the previous work of Sonnenberg
et al. and Woodhall [8, 11], who applied PS re-weighting and sen-
sitivity/specificity corrections. The analysis here differs from the
earlier ones in several ways. First, we have altered the weights as
our target was the general British female population aged 16–
44, rather than the population of sexually experienced women.
Second, we used slightly different corrections for sensitivity and
specificity, and implemented them in a Bayesian way, which
ensure that probability estimates remain in the (0.1) interval,
Table 2. Posterior estimates for the mean change in CT prevalence between 2000 and 2010 under different scenarios
Se-Sp-corrected PS re-weighting Non-response
Scenario number Sensitivity analyses scenarios 18–24 25–44 18–24 25–44 18–24 25–44
0 Base casea −0.27 −0.31 0.04 −0.23 −0.63 −0.37
1 Prior specificity LCx = 99.5 (95% CrI 99.1–99.9) 0.49 0.24 0.60 0.20 0.29 0.33
2 Sensitivity LCx 3.0% less than AC2 −0.33 −0.33 −0.02 −0.24 −0.70 −0.39
3 OR 2000 = OR 2010 = 1.90 −0.27 −0.31 0.04 −0.23 −0.63 −0.41
4 OR 2000 = 1.48, OR 2010 10% higher −0.27 −0.31 0.04 −0.23 −0.31 −0.28
5 OR 2000 = 1.90, OR 2010 10% higher −0.27 −0.31 0.04 −0.23 −0.23 −0.29
aBase-case assumptions: prior LCx specificity 99.8 (95% CrI 99.7–99.9); LCx sensitivity 1.5% less than AC2.
Non-response OR = 1.48 and remains the same for both 2000 and 2010.
Table 3. Impact summary of structural uncertainty: absolute difference (in
bold) between different contrasting scenarios in posterior estimates of
prevalence change, and how these are derived from Table 2, (in parentheses)
Contrast – difference in
estimates
Age 18–24
difference in
estimates of
prevalence change
Age 25–44
difference in
estimates of
prevalence change
PS reweighting vs.
non-response
adjustment, base-case
scenario
(0.04 to
−0.63):0.66
(−0.23 to
−0.37):0.14
99.5% LCx specificity vs.
99.8%
(a) PS reweighting (0.60–0.04):0.56 (0.20 to
−0.23):0.43
(b) Non-response
correction
(0.29 to
−0.63):0.92
(0.33to
−0.37):0.70
Non-response
correction 2010 10%
higher than 2000 vs.
same OR = 1.48
(−0.31 to
−0.63):0.32
(−0.28 to
−0.37):0.10
Non-response
correction 2010 10%
higher than 2000 vs.
same OR = 1.90
(−0.23 to
−0.63):0.40
(−0.29 to
−0.37):0.09
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and hence rule out negative prevalence estimates. Both test accur-
acy and PS reweighting corrections tend to slightly lower preva-
lence. Thirdly, as an alternative to PS re-weighting, we have
assumed that non-responders have a different CT prevalence
than responders, and we have used the OR for non-responder
vs. responder from the ClaSS study [18, 19] to illustrate the poten-
tial impact of a non-response correction. This type of adjustment
raises CT prevalence.
Our main finding is that the 95% CrI for observed CT preva-
lence change alone, setting aside the different methods and types
of adjustment, itself spans 4.8%, obscuring even the largest preva-
lence change that could be considered plausible. This is the direct
result of the small achieved sample size of the urine surveys.
A second major finding is that the impact of any one of three
sources of structural uncertainty would be enough to either
reverse or double any likely true change. We identified the follow-
ing sources of structural uncertainty: method for correcting for
non-response rate (PS reweighting or non-response correction),
test specificity and different non-response corrections in the
two surveys. Test sensitivity and overall level of non-response cor-
rection had little impact on results.
We conclude that although Natsal provides key data on sexual
and reproductive health in the British general population, the sur-
veys are unlikely to generate useful evidence on overall CT preva-
lence, or trends in CT prevalence, unless much larger surveys can
be run, either with greatly improved response rates or superior
methods are found for addressing the likely biases due to low
response rates – challenges that are not unique to Natsal but
that apply across the survey industry.
Results are exquisitely sensitive to assumptions about specifi-
city of the LCx assay. More work could possibly be done synthe-
sising results from earlier literature. This is a difficult area: most
assessments of test accuracy in the absence of a ‘gold standard’
use a ‘composite reference standard’ [27, 28], a method that is
known to always produce biased results [29].
On the issue of non-participation biases, the Natsal surveys,
especially when viewed in conjunction with other sources of
information on CT epidemiology may themselves be a wealth of
information on the mechanisms of non-response, and on the
risk factors for CT infection, even though as this paper suggests,
estimates of absolute prevalence may be of very limited use. For
example, changes in reported sexual behaviour between Natsal-2
and -3, in which number of partners, and extent of risky practices
increased, although not to a great extent [30], would lead us to
expect a rise in CT prevalence. Another example is that although
55% of 16–24 years old women reported being tested for CT dur-
ing the previous year [31], the reported coverage of testing in the
NCSP was only 41% [32], which includes what may be up to 31%
repeat tests [33]. Thus, relative to the general population, a far
higher proportion of Natsal-3 responders would have been tested
and if CT positive they would have been treated, lowering the CT
prevalence in responders, and hence the observed CT prevalence
quite considerably.
These and other biases could be potentially addressed by selec-
tion modelling [34]. Heckman-type selection models although
uncommon in the biomedical literature have been used for
more than three decades in economics and social science litera-
ture [35]. The approach relies on a correlation parameter linking
survey participation and infection status. Model identifiability
improves by including selection variables obeying an exclusion
restriction, to the effect that variables that are strong predictors
of survey participation but are unrelated to infection status.
An alternative approach to monitoring CT prevalence in the
UK has been proposed [36, 37], which relies on a three-
compartment model of infection and diagnosis, and which
makes use of the UK data on coverage of testing and diagnosis
rates. The results are not incompatible with Natsal findings.
However, the core assumption which allows changes in coverage
and diagnosis rates to be mapped into changes in prevalence is
that treatment-seeking and diagnosis-seeking behaviour has
stayed constant. Whether this is indeed the case is debatable
[38] but would seem unlikely as increased knowledge about the
risk of chlamydia and its consequences as a result of the local
and national awareness campaigns linked to the NCSP is likely
to have increased diagnostic testing-seeking behaviour in asymp-
tomatic women after a potential exposure [39]. In addition, the
results point to little change in prevalence after 2000, until
2008–2010, which coincides with the date when the methods
for recording coverage and diagnosis rates changed [32].
However, now that comprehensive recording systems are rou-
tinely providing consistent routine data, this method could be fur-
ther refined, especially if it could be modified to incorporate data
on health-seeking behaviour.
Another alternative might be to develop serological markers
[12] of previous or recent infection in carefully chosen sentinel
populations, such as women attending GU Medicine clinics or
antenatal care. These are not general population samples, but
they are samples which do suffer from non-response bias, in rela-
tively stable populations, whose sexual and reproductive health
are especially relevant. Time trends in age-specific markers of
CT infection in such populations would be highly informative
for policy makers and could be measured with precision and
accuracy.
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be found at https://doi.org/10.1017/S0950268819000347.
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